Johnson & Johnson highlighted the Phase II therapy AL-8178 for respiratory syncytial virus (RSV) on 30 September when it announced the $1.75bn acquisition of Alios BioPharma, but the most valuable aspect of the deal may be the privately-held company's preclinical hepatitis C virus (HCV) programs.
Nucleotide analogs – otherwise known as "nucs" – are hot properties in HCV given their role in all-oral, interferon-free regimens...
Welcome to Scrip
Create an account to read this article
Already a subscriber?